ComplianceOnline

Determination of Regulatory Review Period for Purposes of Patent Extension; AFINITOR

  • Date: May 03, 2010
  • Source: www.fda.gov
Webinar All Access Pass Subscription Abstract:

The Food and Drug Administration (FDA) has determined the regulatory review period for AFINITOR and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.

Bookmark and Share

Trending Compliance Trainings

Trial Master File and Clinical Data Management Regulated by FDA
By - Carolyn Troiano
On Demand Access Anytime
Good Documentation Practice and Record Keeping Regulations (FDA & EMA)
By - Dr. Afsaneh Motamed Khorasani
On Demand Access Anytime
GAMP Data Integrity 21 CFR Part 11 Training Course
By - Kelly Thomas
On Demand Access Anytime
NEW Reclamation Process - Fed Gov't Payments
By - Donna K Olheiser
Live February 11, 2026
Understanding and Preparing for FDA Pharmaceutical Inspections
By - Michael Ferrante
On Demand Access Anytime
How to conduct an effective BSA Audit
By - Justin Muscolino
On Demand Access Anytime
Installation and Qualification of the Packaging Lines
By - John E Lincoln
On Demand Access Anytime
Best Sellers
You Recently Viewed
    Loading